Unicycive Therapeutics, Inc. UNCY
focused on identifying, developing, and commercializing innovative therapies to address significant unmet medical needs, with an initial
focus on kidney disease. Founded in 2016, Unicycive was established to create a streamlined and efficient drug development platform capable
of accelerating the advancement of promising therapies from discovery to commercialization. Currently, our two programs are focused on
kidney disease, an area we believe we have the potential to offer medical benefit. Our initial focus is on developing drugs and getting
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | $675.0K | $951.0K | — | — | — |
| R&D | $9.1M | $20.0M | $12.9M | $12.4M | $6.1M | $1.0M | — |
| SG&A | $20.4M | $12.1M | $8.5M | $6.6M | $245.0K | $58.0K | — |
| Total operating expenses | $29.5M | $32.1M | $21.4M | $19.0M | $9.0M | $2.0M | — |
| Operating income | -$29.5M | -$32.1M | -$20.8M | -$18.1M | -$9.0M | -$2.0M | — |
| Interest expense | $71.0K | $71.0K | $82.0K | $6.0K | $628.0K | $244.0K | — |
| Net income | -$26.6M | -$36.7M | -$30.5M | -$18.1M | -$10.0M | -$2.3M | — |
| EPS, basic | -1.67 | -5.65 | -1.28 | -1.20 | -0.86 | -0.27 | — |
| EPS, diluted | -1.67 | -5.65 | -1.28 | -1.20 | -0.86 | — | — |
| Shares, diluted (wtd. avg.) | $15.9M | $6.7M | $24.5M | $15.1M | $11.7M | $8.5M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $29.2M | $26.1M | $9.7M | $455.0K | $16.6M | — | $15.0K |
| Short-term investments | $12.1M | — | — | — | — | — | — |
| Inventory | — | — | — | $2.2M | $1.8M | — | — |
| Total current assets | $49.0M | $30.9M | $13.4M | $2.6M | $18.4M | $204.0K | — |
| Property, plant and equipment | $66.0K | $75.0K | $26.0K | $22.0K | $28.0K | — | — |
| Total assets | $49.1M | $31.7M | $14.2M | $2.8M | $18.7M | $204.0K | — |
| Accounts payable | $383.0K | $1.1M | $839.0K | $892.0K | $742.0K | $184.0K | — |
| Total current liabilities | $18.9M | $24.1M | $17.5M | $3.3M | $2.1M | $2.9M | — |
| Total liabilities | $18.9M | $24.2M | $18.0M | $3.3M | $2.3M | $2.9M | — |
| Retained earnings | -$127.8M | -$101.3M | -$64.5M | -$34.0M | -$15.9M | -$5.9M | — |
| Total equity | $30.2M | $7.4M | -$3.8M | -$466.0K | $16.5M | -$2.7M | -$884.0K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$31.3M | -$28.6M | -$18.3M | -$15.7M | -$5.8M | -$1.5M | — |
| Depreciation and amortisation | $34.0K | $22.0K | $9.0K | $7.0K | $468.0K | $63.0K | — |
| Stock-based compensation | $2.6M | $2.4M | $1.8M | $1.0M | $966.0K | — | — |
| Capital expenditure | $24.0K | $72.0K | $12.0K | $2.0K | $29.0K | — | — |
| Investing cash flow | -$12.1M | -$72.0K | -$12.0K | -$2.0K | -$29.0K | — | — |
| Financing cash flow | $46.5M | $45.1M | $27.5M | -$471.0K | $22.4M | $1.4M | — |
| Dividends paid | — | $1.1M | $900.0K | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-035903.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |